Condition: Ulcerative Colitis · Sponsor: Takeda
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks. Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| Digestive Health Specialsits | Dothan, Alabama, United States | Recruiting |
| GI Alliance Sun City | Sun City, Arizona, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| Hoag Hospital Newport Beach | Newport Beach, California, United States | Recruiting |
| Endoscopic Research Inc | Orlando, Florida, United States | Recruiting |
| Alliance Clinical Research of Tampa, LLC | Tampa, Florida, United States | Recruiting |
| Gastroenterology Consultants, P.C. | Roswell, Georgia, United States | Recruiting |
| University of Chicago Medicine | Chicago, Illinois, United States | Recruiting |
| GI Alliance - Illinois Gastroenterology Group - Glenview | Glenview, Illinois, United States | Recruiting |
| GI Alliance - Illinois Gastroenterology Group LLC - Gurnee | Gurnee, Illinois, United States | Recruiting |
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| University of Louisville | Louisville, Kentucky, United States | Recruiting |
+ 37 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06095128